Attitudes and eligibility of long-acting cabotegravir/rilpivirine treatment among youth living with HIV in a clinical and national cohort in Thailand: a cross-sectional study
Open Access
- 18 July 2025
- journal article
- research article
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 22 (1) , 1-9
Abstract
Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) is the only available approved injectable antiretroviral therapy (ART) for youth living with HIV (YLHIV). However, it is not yet available through the Thai National AIDS Program (NAP). This study assessed Thai YLHIV attitudes toward LA-CAB/RPV and identified the proportion of medically eligible YLHIV within the NAP. Two cross-sectional studies were conducted, the first study conducted in an HIV clinic in Bangkok involving YLHIV aged 13–24 years, assessing attitudes via questionnaires. The second study analyzed medical eligibility among 14,670 youth aged 12–24 years in the NAP, defined by current HIV RNA < 50 copies/ml, no prior treatment failure (HIV RNA < 1,000 copies/ml) and no suspected archived resistance to CAB/RPV. Logistic regression was performed to identify factors associated with willingness and eligibility. From April to June 2024, 100 YLHIV (median age 20 years; IQR 19.0-21.7) were enrolled, 71% had non-perinatally acquired HIV (non-PHIV). Overall, 85% expressed willingness to use LA-CAB/RPV. Non-PHIV youth showed significantly higher interest (93.0% vs. 65.5%); OR 6.9 [95% CI: 2.1–22.8], despite a shorter median treatment duration (2.7 vs. 14.3 years). LA-CAB/RPV was considered more convenient than pills by 76%, although 42% anticipated injection-site reactions. Among YLHIV in the NAP (median age 22 years; IQR 20–23), 64% were medically eligible, non-PHIV youth also had a higher eligibility proportion (70% vs. 32%) with an aOR 2.0 [95% CI: 1.7–2.4]. The majority of Thai YLHIV showed positive attitudes towards LA-CAB/RPV, with two-thirds meeting medical eligibility criteria. Enhancing access to generic formulations of this regimen could significantly impact lifelong HIV management.Keywords
This publication has 30 references indexed in Scilit:
- Multisite Study of Women Living With HIV's Perceived Barriers to, and Interest in, Long-Acting Injectable Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2020
- “I feel empowered”: women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and SpainCulture, Health & Sexuality, 2020
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionNew England Journal of Medicine, 2020
- Interest of Youth Living With HIV in Long-Acting AntiretroviralsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2019
- Attrition and treatment outcomes among adolescents and youths living with HIV in the Thai National AIDS ProgramJournal of Virus Eradication, 2019
- HIV-1 drug resistance and resistance testingInfection, Genetics and Evolution, 2016
- Relationship between viral load and self-report measures of medication adherence among youth with perinatal HIV infectionAIDS Care, 2013
- Barriers to Medication Adherence in Behaviorally and Perinatally Infected Youth Living with HIVAIDS and Behavior, 2012
- HIV‐1 drug resistance mutations in children after failure of first‐line nonnucleoside reverse transcriptase inhibitor‐based antiretroviral therapyHIV Medicine, 2010
- Predictors of Virologic Failure and Genotypic Resistance Mutation Patterns in Thai Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral TherapyThe Pediatric Infectious Disease Journal, 2009